BioArctic AB, a Swedish research based biopharma company, has signed an extended research collaboration agreement with Uppsala University, Department of Pharmaceutical Biosciences. The extended research collaboration concerns technologies for increased passage across the blood-brain barrier and BioArctic will contribute financial support for a three year post-doc research position.

The blood-brain barrier is a membrane that controls the exchange of substances between the blood and the brain. The barrier protects the brain from toxins and pathogens, but it also makes it more difficult to deliver therapeutic agents to the brain. Under an earlier collaboration with Uppsala University, BioArctic develops a technology that facilitates the passage of antibodies across the blood-brain barrier. This project is in research phase.

The new extended research collaboration aims to develop innovative technologies to increase the passage of antibodies also into nerve cells. This can be of great value for the diagnosis and treatment of neuro degenerative diseases such as Alzheimer’s and Parkinson’s disease.

“We are looking forward to this extended research collaboration since BioArctic is keen to improve the diagnosis as well as the treatment for severe neuro degenerative disease such as Alzheimer’s and Parkinson’s disease,” said Gunilla Osswald, CEO of BioArctic.

BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neuro degenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for complete spinal cord injury.